Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy
暂无分享,去创建一个
[1] J. E. Tanner,et al. Spin diffusion measurements : spin echoes in the presence of a time-dependent field gradient , 1965 .
[2] H. Weinmann,et al. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. , 1984, Physiological chemistry and physics and medical NMR.
[3] D. Le Bihan,et al. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. , 1988, Radiology.
[4] D. Norris,et al. Biexponential diffusion attenuation in various states of brain tissue: Implications for diffusion‐weighted imaging , 1996, Magnetic resonance in medicine.
[5] P. Tofts. Modeling tracer kinetics in dynamic Gd‐DTPA MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.
[6] J. Witjes,et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. , 1998, Radiology.
[7] W E Reddick,et al. Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma , 1999, Journal of magnetic resonance imaging : JMRI.
[8] Toshinori Hirai,et al. Usefulness of diffusion‐weighted MRI with echo‐planar technique in the evaluation of cellularity in gliomas , 1999, Journal of magnetic resonance imaging : JMRI.
[9] M. Knopp,et al. Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.
[10] R. Gonzalez,et al. Diffusion-weighted MR imaging of the brain. , 2000, Radiology.
[11] W. Rooney,et al. Determination of the MRI contrast agent concentration time course in vivo following bolus injection: Effect of equilibrium transcytolemmal water exchange , 2000, Magnetic resonance in medicine.
[12] Olav Haraldseth,et al. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging , 2000, Magnetic resonance in medicine.
[13] P. Ellen Grant,et al. Diffusion-weighted MR imaging of the brain. , 2000, Radiology.
[14] R. Edelman,et al. Semiquantitative assessment of uterine perfusion using first pass dynamic contrast-enhanced MR imaging for patients treated with uterine fibroid embolization. , 2000, Journal of magnetic resonance imaging : JMRI.
[15] J. Geschwind,et al. Chemoembolization of liver tumor in a rabbit model: assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis. , 2000, Journal of vascular and interventional radiology : JVIR.
[16] Rakesh K. Jain,et al. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.
[17] D P Dearnaley,et al. Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. , 2001, Radiology.
[18] C T Moonen,et al. Diffusion tensor MRI of the human kidney , 2001, Journal of magnetic resonance imaging : JMRI.
[19] David L Buckley,et al. Uncertainty in the analysis of tracer kinetics using dynamic contrast‐enhanced T1‐weighted MRI , 2002, Magnetic resonance in medicine.
[20] A. Padhani,et al. Reproducibility of dynamic contrast‐enhanced MRI in human muscle and tumours: comparison of quantitative and semi‐quantitative analysis , 2002, NMR in biomedicine.
[21] David L Buckley,et al. Transcytolemmal water exchange and its affect on the determination of contrast agent concentration in vivo , 2002, Magnetic resonance in medicine.
[22] Jean-Luc Daire,et al. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. , 2003, Radiology.
[23] Paul A Meyers,et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. , 2003, Radiology.
[24] K. Hayashi,et al. Discrimination of metastatic cervical lymph nodes with diffusion-weighted MR imaging in patients with head and neck cancer. , 2003, AJNR. American journal of neuroradiology.
[25] Stephan E Maier,et al. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Martin A Lodge,et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] G. Sevlever,et al. Characterization of brain tumors by MRS, DWI and Ki-67 labeling index , 2005, Journal of Neuro-Oncology.
[28] G J M Parker,et al. Analysis of MR diffusion weighted images. , 2004, The British journal of radiology.
[29] H. Schlemmer,et al. Can preoperative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? , 2004 .
[30] H. Schlemmer,et al. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? , 2004, European Radiology.
[31] R. Gillies,et al. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. , 2004, Neoplasia.
[32] A. Padhani,et al. Perfusion MR Imaging of Extracranial Tumor Angiogenesis , 2004, Topics in magnetic resonance imaging : TMRI.
[33] J E Husband,et al. Evaluation of the response to treatment of solid tumours – a consensus statement of the International Cancer Imaging Society , 2004, British Journal of Cancer.
[34] A. Padhani,et al. Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI , 2005, British Journal of Cancer.
[35] J R Griffiths,et al. Clinical studies. , 2005, Advances in pharmacology.
[36] Benjamin M Yeh,et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Philippe Lambin,et al. Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. , 2005, International journal of radiation oncology, biology, physics.
[38] Bradford A Moffat,et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[39] P Kelly Marcom,et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Mathias Langer,et al. Osteosarcoma: Preliminary Results of In Vivo Assessment of Tumor Necrosis After Chemotherapy With Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging , 2006, Investigative radiology.
[41] Peter Gibbs,et al. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. , 2006, Magnetic resonance imaging.
[42] I. Wilkinson,et al. Dexamethasone and Enhancing Solitary Cerebral Mass Lesions: Alterations in Perfusion and Blood-tumor Barrier Kinetics Shown by Magnetic Resonance Imaging , 2006, Neurosurgery.
[43] Paul Workman,et al. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. , 2006, Journal of the National Cancer Institute.
[44] T. Hirai,et al. Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: initial results , 2006, European Radiology.
[45] Carmel Hayes,et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. , 2006, Radiology.
[46] T. Hirai,et al. Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. , 2006, AJNR. American journal of neuroradiology.
[47] Ethaar El-Emir,et al. Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down. , 2007, International journal of oncology.
[48] M. Kurrer,et al. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed? , 2007, Radiology.
[49] Haesun Choi,et al. We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] John A Butman,et al. Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. , 2007, Neoplasia.
[51] Neil J Sebire,et al. Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity. , 2007, Radiology.
[52] B. Ross,et al. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] T. Yankeelov,et al. Measuring Tumor Perfusion in Control and Treated Murine Tumors , 2007, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[54] Tracy T Batchelor,et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.
[55] Timothy D Johnson,et al. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. , 2007, Neoplasia.
[56] E. Scurr,et al. Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination , 2008, European Radiology.
[57] G. Parker,et al. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents , 2007, British Journal of Cancer.
[58] D. Collins,et al. Dynamic MRI for imaging tumor microvasculature: Comparison of susceptibility and relaxivity techniques in pelvic tumors , 2007, Journal of magnetic resonance imaging : JMRI.
[59] D J Collins,et al. Reproducibility of reference tissue quantification of dynamic contrast-enhanced data: comparison with a fixed vascular input function , 2007, Physics in medicine and biology.
[60] Yutaka Imai,et al. Relation between cancer cellularity and apparent diffusion coefficient values using diffusion-weighted magnetic resonance imaging in breast cancer , 2008, Radiation Medicine.
[61] D. Bluemke,et al. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. , 2007, Journal of vascular and interventional radiology : JVIR.
[62] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[63] Thomas E Yankeelov,et al. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. , 2007, Magnetic resonance imaging.
[64] D. Collins,et al. Diffusion-weighted MRI in the body: applications and challenges in oncology. , 2007, AJR. American journal of roentgenology.
[65] Geoff J M Parker,et al. Imaging Tumor Vascular Heterogeneity and Angiogenesis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging , 2007, Clinical Cancer Research.
[66] Katsuyuki Nakanishi,et al. Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images. , 2007, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.
[67] L. Shen,et al. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. , 2008, Radiology.
[68] Teresa McShane,et al. Scan‐rescan variability in perfusion assessment of tumors in MRI using both model and data‐derived arterial input functions , 2008, Journal of magnetic resonance imaging : JMRI.
[69] D. Mankoff,et al. Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer. , 2008, Academic radiology.
[70] Timothy D Johnson,et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] A. Harris,et al. A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors , 2008 .
[72] Mark L. Greenberg,et al. Medical care in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] W. Scheithauer,et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] E. Squillaci,et al. Malignant renal neoplasms: correlation between ADC values and cellularity in diffusion weighted magnetic resonance imaging at 3 T , 2008, La radiologia medica.
[75] Michael E Phelps,et al. Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs , 2008, Nature Clinical Practice Oncology.
[76] William E Grizzle,et al. Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. , 2008, Radiology.
[77] Andreas Makris,et al. Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer , 2008, Clinical Cancer Research.
[78] Robert J. Gillies,et al. Causes and Consequences of Increased Glucose Metabolism of Cancers , 2008, Journal of Nuclear Medicine.
[79] Gregory Karczmar,et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] M.-Y.L. Su. Inflammatory Breast Cancer: Dynamic Contrast-enhanced MR in Patients Receiving Bevacizumab—Initial Experience , 2008 .
[81] K. Flaherty,et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma , 2008, Cancer biology & therapy.
[82] Mark W. Dewhirst,et al. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response , 2008, Nature Reviews Cancer.
[83] David J Collins,et al. Technology Insight: water diffusion MRI—a potential new biomarker of response to cancer therapy , 2008, Nature Clinical Practice Oncology.
[84] Geoff J M Parker,et al. Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging , 2009, Clinical Cancer Research.
[85] M. Schwaiger,et al. Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer , 2009, Journal of oncology.
[86] Y. Liu,et al. Diffusion-Weighted Magnetic Resonance Imaging of Uterine Cervical Cancer , 2009, Journal of computer assisted tomography.
[87] Evis Sala,et al. Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer. , 2009, International journal of radiation oncology, biology, physics.
[88] Timothy D Johnson,et al. The parametric response map is an imaging biomarker for early cancer treatment outcome , 2009, Nature Medicine.
[89] Gary Liney,et al. Correlation of diffusion‐weighted magnetic resonance data with cellularity in prostate cancer , 2009, BJU international.
[90] J E Heiserman,et al. Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements , 2009, American Journal of Neuroradiology.
[91] H. R. Arvinda,et al. RETRACTED ARTICLE: Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging , 2009, Journal of Neuro-Oncology.
[92] Walter H Backes,et al. Vessel growth and function: depiction with contrast-enhanced MR imaging. , 2009, Radiology.
[93] P. Choyke,et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. , 2009, Neoplasia.
[94] M. Okada,et al. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.
[95] J. Jesberger,et al. A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers , 2009, Clinical Cancer Research.
[96] Bin Wang,et al. Diffusion‐weighted imaging of prostate cancer: Correlation between apparent diffusion coefficient values and tumor proliferation , 2009, Journal of magnetic resonance imaging : JMRI.
[97] R. Kauppinen,et al. Monitoring of gliomas in vivo by diffusion MRI and 1H MRS during gene therapy‐induced apoptosis: interrelationships between water diffusion and mobile lipids , 2009, NMR in biomedicine.
[98] R. Jain,et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[99] Hon J. Yu,et al. Residual Breast Cancer Diagnosed by MRI in Patients Receiving Neoadjuvant Chemotherapy with and Without Bevacizumab , 2009, Annals of Surgical Oncology.
[100] A. Levy,et al. Focal Liver Lesion Detection and Characterization with Diffusion-weighted MR Imaging: Comparison with Standard Breath-hold T2-weighted Imaging , 2009 .
[101] Brandon Whitcher,et al. Quantifying spatial heterogeneity in dynamic contrast‐enhanced MRI parameter maps , 2009, Magnetic resonance in medicine.
[102] Pt Sutton,et al. Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial , 2010 .
[103] Anwar R. Padhani,et al. Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[104] Edward Ashton,et al. Dynamic Contrast-Enhanced Magnetic Resonance Imaging , 2012, Definitions.